Introduction
Hemoglobinopathies such as sickle cell disease (SCD) and b-thalassemia cause substantial morbidity and mortality. SCD affects nearly 100 000 people in the United States. Bone marrow transplant (BMT) from a nonaffected donor, usually a human lymphocyte antigen (HLA)-matched sibling, is the only known curative therapy [1] [2] [3] 4 ]. The indications for BMT in patients with SCD are not well established, but selection criteria have been proposed. Ideally, patients should be less than 16 years of age, have an HLA-identical related donor, and have at least one of the following signs or symptoms: stroke or central nervous system event lasting for more than 24 h, acute chest syndrome, recurrent severe pain episodes, impaired neuropsychological function with an abnormal MRI scan, stage I or II sickle lung disease, sickle nephropathy, bilateral proliferative retinopathy, osteonecrosis of multiple joints, or red blood cell alloimmunization during long-term transfusion therapy [1] . The majority of the series published so far report on patients with advanced disease that meet the above criteria [1, 2, 4 ]. However, sickle cell patients, their families, and their physicians are often reluctant to pursue BMT because of the inherent risk of morbidity and mortality. Even a relatively low mortality rate following BMT may be difficult to accept in a child with SCD given that the average life span for SCD is now over 40 years of age. Chakrabarti and Bareford [5 ] surveyed 30 adult patients with SCD about their feelings towards receiving a reduced-intensity BMT for the management of their disease. Sixty-two percent were willing to accept a 10% transplant-related mortality, and a third of patients were willing to accept a 30% transplant-related mortality. A similar number, 62% accepted a 10% risk of graft failure. Fifty percent were willing to accept infertility, but only 20% considered chronic graft-versus-host disease (GVHD) as an acceptable alternative. Overall, 60% of those surveyed would consider joining a clinical trial of reduced-intensity BMT. These results suggest that many SCD patients are willing to accept relatively high toxicities for a potentially curative therapy. the first 'large' series of BMT for SCD. Twenty-two children with SCD received an HLA-identical sibling BMT after receiving busulfan, cyclophosphamide, and antithymocyte globulin (ATG) or alemtuzumab-based regimens. All patients were less than 16 years of age and had 'advanced' disease (history of stroke, recurrent acute chest syndrome, abnormal brain imaging, retinopathy or bone disease, etc.). Ninety percent of the patients were alive after 2 years of follow-up, and 72% had stable chimerism. Graft rejection was low (18%); however, neurologic events, including seizures and cerebral hemorrhage, occurred in seven patients.
In Belgium, Vermylen et al. [3] reported on 50 patients with SCD who received an HLA-matched sibling BMT using bone marrow (48 patients) or cord blood (two patients) after conditioning with busulfan and cyclophosphamidebased regimens (some patients also received total lymphocyte irradiation or antithymocyte globulin). In these 50 patients, there were two groups; group I included 36 patients with symptomatic SCD fulfilling the criteria that were discussed earlier, and group II included 14 patients with asymptomatic disease (less than three transfusions of red blood cells). Median age at time of BMT was 7.5 (range, 0.9-23) years, and the probability of survival was 93%. Acute GVHD occurred in 20 patients, and one patient developed acute leukemia. Group II had better outcome than group I [overall survival (OS) of 100 versus 88% and event-free survival of 93 versus 76%].
Walters et al. [2] reported on an additional 50 patients with symptomatic SCD transplanted between 1991 and 1999. These patients received matched sibling bone marrow grafts after conditioning with busulfan and cyclophosphamide and either ATG or alemtuzumab. The median age in this trial was 9.9 (range, 3.3-15.9) years. OS was 94%, event-free survival was 84%, and an improvement in pulmonary and neurological parameters was observed. One patient died from intracranial bleed, and two died from complications of chronic GVHD. There were five cases of graft rejection.
More recently, Bernaudin et al. [4 ] reported results of 87 patients transplanted for SCD. Neurological complications were the main indication for BMT. Stem cells were harvested from bone marrow in 74 patients and from cord blood in 10 patients, bone marrow and cord blood in two patients, and peripheral blood stem cells in one patient. The conditioning regimen consisted of cyclophosphamide and busulfan; however, ATG was added to the conditioning regimen after the first 12 cases due to a high rate of graft failure (four out of 12 cases). After the addition of ATG, the rate of graft failure was just 3%. OS was 93% at 6 years. This group developed a strict protocol for prevention of neurological complications after BMT, involving the administration of clonazepam starting on day 8 and continuing for as long as the patient remained on cyclosporine. The investigators kept tight control of arterial hypertension, transfused red blood cells to maintain hemoglobin levels over 90 g/l, and transfused platelets to maintain a platelet count greater than 50 Â 10 9 /l. On the basis of the results of this relatively large study, the authors concluded that HLA-identical sibling BMT after myeloablative conditioning should be considered as the standard of care for children with SCD.
The Center for International Blood and Marrow Transplant Research reported outcomes after myeloablative BMT from HLA-matched sibling donors in 67 patients with SCD transplanted between 1989 and 2002 [7 ] . The most common indications for BMT were neurological events and recurrent vasoocclusive crisis in 38 and 37% of patients, respectively. The median age at transplantation was 10 years, and 67% of patients were heavily transfused before BMT. Twenty-seven percent of patients had a poor performance status at transplantation. Ninety-four percent received busulfan and cyclophosphamide-based regimens, and bone marrow was the most common source of hematopoietic stem cells. Sixty-four of 67 patients are alive with 5-year probabilities of disease-free survival and OS of 85 and 97%, respectively. Nine patients had graft failure with recovery of sickle erythropoiesis.
In summary, results of HLA-matched sibling BMT following a myeloablative conditioning regimen for children with SCD are encouraging. The risk of graft failure is 5-10%, the risk of acute GVHD is 15-20%, the risk of chronic GVHD is 10-20%, and overall and event-free survival are roughly 90 and 80%, respectively. A brief summary of the outcomes can be seen in Table 1 .
Reduced-intensity preparative regimens
Because of end-organ damage from SCD (e.g., pulmonary, renal, hepatic, etc.), there is great interest in performing reduced-intensity BMT for SCD. Successful application of this approach would make more SCD patients eligible for BMT, as end-organ toxicity often excludes patients from myeloablative conditioning regimens such as busulfan and cyclophosphamide. Unfortunately, the risk of graft failure following reduced-intensity BMT for SCD is very high. Jacobsohn et al. [8] studied 13 pediatric patients with nonmalignant disorders who underwent a reduced-intensity BMT. A uniform preparative regimen consisting of fludarabine, busulfan, and ATG was used. The 1-year OS was 84%, but three of the four patients transplanted for a hemoglobinopathy rejected their graft. These findings have been duplicated in other small studies [9, 10] . Nevertheless, Horwitz et al. [11] reported the outcome of two adult patients with SCD who received a fludarabine, total body irradiation, alemtuzumab, and cyclophosphamide conditioning regimen followed by transplant of peripheral blood stem cells. The transplants were successful in both patients, and at 20 months, no GVHD was diagnosed in either patient.
Long-term side effects
Late side effects are another concern for patients undergoing BMT for SCD. As these transplants are usually done in children, the effects on growth and development are relevant. Eggleston et al. [12 ] studied growth and development in 53 children with SCD who received a BMT. In these patients, growth was not affected unless the transplant was carried out near the growth spurt of adolescence. Another cohort of children reported by Brachet et al. [13 ] was followed for growth and gonadal function after BMT for SCD. There were no problems with growth; however, gonadal function was severely compromised. Only three out of 10 girls were able to sustain ovarian function (menses and pubertal development); one successful pregnancy was reported. All boys had normal pubertal development, but all had small testis and most had increased folliclestimulating and luteinizing hormone levels as well as low-to-normal testosterone levels. Two boys had a spermogram, one had oligospermia, and one had azoospermia. The study by Bernaudin et al. [14 ] also failed to show any growth abnormalities after BMT for SCD but did show a significant number of girls having ovarian failure, and only five out of 17 girls had spontaneous puberty.
Other benefits derived from transplantation
Mixed chimerism is considered an undesirable outcome of BMT in patients with hematologic malignancies and is common in SCD. For patients with SCD who are 'mixed chimeras', there are still important health benefits. Wu et al. [15 ] reported on nine patients who were mixed chimeras after BMT for SCD. These authors documented improvement in markers of intravascular hemolysis (e.g., lactate dehydrogenase and free hemoglobin) as well as markers of vascular function (e.g., plasma nitric oxide consumption and soluble vascular adhesion molecule-1 levels) after BMT. Thus, mixed chimerism, if maintained, can result in marked clinical improvement in patients with SCD.
Alternative donors for sickle cell disease patients
The greatest barrier to more widespread use of BMT to cure SCD is the lack of a suitable HLA-identical donor. Walters et al. [2] reported that among the 4848 sickle cell patients less than 16 years of age who were followed in 22 centers, only 315 (6.5%) fulfilled protocol entry criteria for BMT. Among these 315 eligible patients, 128 (2.6% of the original group) had HLA typing performed, and of these, 44 had an HLA-identical sibling, just 0.9% of the original 4848 patients. Thus, less than 1% of patients with SCD will have a suitable HLA-identical sibling donor. These data underscore the point that if BMT is to become more widely available to treat SCD, novel strategies that address expanding the donor pool will be necessary. Three major sources of alternative donor stem cells for BMT are currently being studied with hopes of making BMT for SCD more widely available: umbilical cord blood and unrelated or haploidentical bone marrow.
Some of the large studies mentioned earlier used cord blood cells as the source of stem cells. Also, small groups of patients receiving umbilical cord cells have been reported with similar OS and event-free survival independent to those reports obtained with bone marrow [16] . Adamkiewicz et al. [17 ] reported on seven children on chronic transfusions with a history of SCD and stroke who received an unrelated cord blood BMT. Five patients received an HLA 4/6 and two an HLA 5/6-unrelated cord blood transplant. Four patients received myeloablative conditioning. Of these, one had primary graft failure and three had sustained engraftment, two with grade III-IV acute GVHD (one of whom died), and one achieved stable mixed chimerism. Three patients treated with reduced-intensity regimens failed to engraft.
In another attempt to expand the donor pool for patients needing a BMT, researchers from Johns Hopkins reported the successful use of reduced-intensity haploidentical BMT. Related haploidentical BMT is an alternative method for expanding the potential pool of bone marrow donors; any patient shares exactly one HLA haplotype with each biologic parent or child, and siblings or half-siblings have a 50% chance of being haploidentical. Historically, the disadvantage of HLA haploidentical BMT has been the high incidence of graft rejection and severe GVHD. The Hopkins group appears to have mitigated many of these drawbacks by incorporating high-dose cyclophosphamide into their GVHD prophylactic regimen. Recently, this group has shown that haploidentical BMT using nonmyeloablative conditioning and highdose, posttransplantation cyclophosphamide is associated with low rates of fatal graft failure, infection, and severe acute GVHD in patients with hematologic malignancies [18] . In this study of 68 patients, most patients with advanced hematologic malignancies, the cumulative incidences of grades II-IV and grades III-IV acute GVHD by day 200 were 34 and 6%, respectively. Non-relapse mortality at one year was 15% [18] . The Hopkins group has also used this approach to treat three patients with paroxysmal nocturnal hemoglobinuria, one of whom also had severe SCD. Rapid engraftment without GVHD occurred in two of the patients, including the patient with SCD. Both patients are disease free with full donor chimerism and require no immunosuppressive therapy, with follow-up of 1 and 4 years, respectively [19 ] .
Conclusion
BMT is a curative option for patients with SCD and other hemoglobinopathies. However, it is clear that the number of transplants performed for this indication is low, and very few studies have been published to guide clinicians. Given the large number of patients at risk (AfricanAmericans, Arabs, and other groups from Mediterranean ancestry), it is clear that this procedure should become more prevalent, and more studies should be ongoing. The major obstacle to more widespread use of BMT for SCD is the paucity of suitable donors. The use of 'alternative' donors would increase the potential pool of donors available to these patients, but important obstacles of toxicity from the conditioning regimen, graft failure, and GVHD must be overcome.
